Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals

Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer science 2018-08, Vol.109 (8), p.2383-2390
Hauptverfasser: Masaki, Ayako, Ishida, Takashi, Suzuki, Susumu, Ito, Asahi, Narita, Tomoko, Kinoshita, Shiori, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Inagaki, Hiroshi, Ueda, Ryuzo, Iida, Shinsuke
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2390
container_issue 8
container_start_page 2383
container_title Cancer science
container_volume 109
creator Masaki, Ayako
Ishida, Takashi
Suzuki, Susumu
Ito, Asahi
Narita, Tomoko
Kinoshita, Shiori
Ri, Masaki
Kusumoto, Shigeru
Komatsu, Hirokazu
Inagaki, Hiroshi
Ueda, Ryuzo
Iida, Shinsuke
description Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease. The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.
doi_str_mv 10.1111/cas.13654
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6113433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2468550104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEoqWw4AVQJDbtIp3j-3iDVI2AQRqJBQNby3FOGJckDnEydHaIJ-AZeRI8nbZcJLBknSP70ycf_1n2lMA5SWvmbDwnTAp-LzsmjOtCAcj7170qNDB6lD2K8RKASa75w-yI6jkXCuhx9m05tbbL1z--fnfYNHmza_tNGIfQezdrcPqErbf51g9TzMddjznJT5fr1YfEk7N8ba9SE3t0vvbulwWvNnaKow9d7rv8lk_bdzW6Eat0XPmtrybbxMfZgzoVfHJTT7L3r16uF8ti9fb1m8XFqnBcC14gnxNbga11hYBWa6pZSUARV8pSYa0sEboEyTRIUTEirXJi7mpXEaIsMHaSvTh4-6lssXLYjYNtTD_41g47E6w3f950fmM-hq2RJH0k2wtObwRD-DxhHE3r435e22GYoqHAFRVEcEjo87_QyzANXRrPUC7nQgAB_l-KaqBUEi0TdXag3BBiHLC-ezIBs8_fpPzNdf6Jffb7jHfkbeAJmB2AL77B3b9NZnHx7qD8CY70vzk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290226196</pqid></control><display><type>article</type><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</creator><creatorcontrib>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</creatorcontrib><description>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease. The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.13654</identifier><identifier>PMID: 29845702</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>adult T‐cell leukemia/lymphoma ; Antigens ; Apoptosis ; Asymptomatic ; Cell death ; CTL ; Cytokines ; Cytotoxicity ; Gene Products, tax - immunology ; HTLV-I Infections - immunology ; HTLV‐1 ; Human T-lymphotropic virus 1 - immunology ; Humans ; Immunoglobulins ; Laboratories ; Leukemia ; Leukemia-Lymphoma, Adult T-Cell - immunology ; Lymphocytes ; Lymphocytes T ; Lymphoma ; Original ; Peptides ; Peripheral blood mononuclear cells ; Pharmaceuticals ; Programmed Cell Death 1 Receptor - immunology ; programmed cell death protein 1 ; Proteins ; R&amp;D ; Research &amp; development ; Research funding ; Risk factors ; T-Lymphocytes, Cytotoxic - immunology ; Tax ; Tumor necrosis factor-TNF</subject><ispartof>Cancer science, 2018-08, Vol.109 (8), p.2383-2390</ispartof><rights>2018 The Authors. published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</citedby><cites>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</cites><orcidid>0000-0002-1060-0777 ; 0000-0002-9617-486X ; 0000-0002-4951-960X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113433/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113433/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1416,11561,27923,27924,45573,45574,46051,46475,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29845702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ishida, Takashi</creatorcontrib><creatorcontrib>Suzuki, Susumu</creatorcontrib><creatorcontrib>Ito, Asahi</creatorcontrib><creatorcontrib>Narita, Tomoko</creatorcontrib><creatorcontrib>Kinoshita, Shiori</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Kusumoto, Shigeru</creatorcontrib><creatorcontrib>Komatsu, Hirokazu</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease. The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</description><subject>adult T‐cell leukemia/lymphoma</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Asymptomatic</subject><subject>Cell death</subject><subject>CTL</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Gene Products, tax - immunology</subject><subject>HTLV-I Infections - immunology</subject><subject>HTLV‐1</subject><subject>Human T-lymphotropic virus 1 - immunology</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemia-Lymphoma, Adult T-Cell - immunology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Original</subject><subject>Peptides</subject><subject>Peripheral blood mononuclear cells</subject><subject>Pharmaceuticals</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>programmed cell death protein 1</subject><subject>Proteins</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Research funding</subject><subject>Risk factors</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tax</subject><subject>Tumor necrosis factor-TNF</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kctu1DAUhiMEoqWw4AVQJDbtIp3j-3iDVI2AQRqJBQNby3FOGJckDnEydHaIJ-AZeRI8nbZcJLBknSP70ycf_1n2lMA5SWvmbDwnTAp-LzsmjOtCAcj7170qNDB6lD2K8RKASa75w-yI6jkXCuhx9m05tbbL1z--fnfYNHmza_tNGIfQezdrcPqErbf51g9TzMddjznJT5fr1YfEk7N8ba9SE3t0vvbulwWvNnaKow9d7rv8lk_bdzW6Eat0XPmtrybbxMfZgzoVfHJTT7L3r16uF8ti9fb1m8XFqnBcC14gnxNbga11hYBWa6pZSUARV8pSYa0sEboEyTRIUTEirXJi7mpXEaIsMHaSvTh4-6lssXLYjYNtTD_41g47E6w3f950fmM-hq2RJH0k2wtObwRD-DxhHE3r435e22GYoqHAFRVEcEjo87_QyzANXRrPUC7nQgAB_l-KaqBUEi0TdXag3BBiHLC-ezIBs8_fpPzNdf6Jffb7jHfkbeAJmB2AL77B3b9NZnHx7qD8CY70vzk</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Masaki, Ayako</creator><creator>Ishida, Takashi</creator><creator>Suzuki, Susumu</creator><creator>Ito, Asahi</creator><creator>Narita, Tomoko</creator><creator>Kinoshita, Shiori</creator><creator>Ri, Masaki</creator><creator>Kusumoto, Shigeru</creator><creator>Komatsu, Hirokazu</creator><creator>Inagaki, Hiroshi</creator><creator>Ueda, Ryuzo</creator><creator>Iida, Shinsuke</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1060-0777</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid></search><sort><creationdate>201808</creationdate><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><author>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>adult T‐cell leukemia/lymphoma</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Asymptomatic</topic><topic>Cell death</topic><topic>CTL</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Gene Products, tax - immunology</topic><topic>HTLV-I Infections - immunology</topic><topic>HTLV‐1</topic><topic>Human T-lymphotropic virus 1 - immunology</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemia-Lymphoma, Adult T-Cell - immunology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Original</topic><topic>Peptides</topic><topic>Peripheral blood mononuclear cells</topic><topic>Pharmaceuticals</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>programmed cell death protein 1</topic><topic>Proteins</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Research funding</topic><topic>Risk factors</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tax</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ishida, Takashi</creatorcontrib><creatorcontrib>Suzuki, Susumu</creatorcontrib><creatorcontrib>Ito, Asahi</creatorcontrib><creatorcontrib>Narita, Tomoko</creatorcontrib><creatorcontrib>Kinoshita, Shiori</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Kusumoto, Shigeru</creatorcontrib><creatorcontrib>Komatsu, Hirokazu</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masaki, Ayako</au><au>Ishida, Takashi</au><au>Suzuki, Susumu</au><au>Ito, Asahi</au><au>Narita, Tomoko</au><au>Kinoshita, Shiori</au><au>Ri, Masaki</au><au>Kusumoto, Shigeru</au><au>Komatsu, Hirokazu</au><au>Inagaki, Hiroshi</au><au>Ueda, Ryuzo</au><au>Iida, Shinsuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2018-08</date><risdate>2018</risdate><volume>109</volume><issue>8</issue><spage>2383</spage><epage>2390</epage><pages>2383-2390</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease. The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>29845702</pmid><doi>10.1111/cas.13654</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1060-0777</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1347-9032
ispartof Cancer science, 2018-08, Vol.109 (8), p.2383-2390
issn 1347-9032
1349-7006
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6113433
source MEDLINE; DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; Wiley Online Library All Journals; PubMed Central
subjects adult T‐cell leukemia/lymphoma
Antigens
Apoptosis
Asymptomatic
Cell death
CTL
Cytokines
Cytotoxicity
Gene Products, tax - immunology
HTLV-I Infections - immunology
HTLV‐1
Human T-lymphotropic virus 1 - immunology
Humans
Immunoglobulins
Laboratories
Leukemia
Leukemia-Lymphoma, Adult T-Cell - immunology
Lymphocytes
Lymphocytes T
Lymphoma
Original
Peptides
Peripheral blood mononuclear cells
Pharmaceuticals
Programmed Cell Death 1 Receptor - immunology
programmed cell death protein 1
Proteins
R&D
Research & development
Research funding
Risk factors
T-Lymphocytes, Cytotoxic - immunology
Tax
Tumor necrosis factor-TNF
title Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A12%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20T%E2%80%90cell%20lymphotropic/leukemia%20virus%20type%201%20(HTLV%E2%80%901)%20Tax%E2%80%90specific%20T%E2%80%90cell%20exhaustion%20in%20HTLV%E2%80%901%E2%80%90infected%20individuals&rft.jtitle=Cancer%20science&rft.au=Masaki,%20Ayako&rft.date=2018-08&rft.volume=109&rft.issue=8&rft.spage=2383&rft.epage=2390&rft.pages=2383-2390&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.13654&rft_dat=%3Cproquest_pubme%3E2468550104%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290226196&rft_id=info:pmid/29845702&rfr_iscdi=true